Update shared on18 Aug 2025
Fair value Increased 9.71%Carysil’s consensus price target has been raised to ₹1039, reflecting a notable improvement in future earnings valuation as indicated by the decline in its forward P/E and a marginal uplift in expected revenue growth.
What's in the News
- Board meeting scheduled to consider investment in a subsidiary company.
- Board meeting planned to review and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2025.
Valuation Changes
Summary of Valuation Changes for Carysil
- The Consensus Analyst Price Target has risen from ₹947.00 to ₹1039.
- The Future P/E for Carysil has significantly fallen from 37.41x to 33.32x.
- The Consensus Revenue Growth forecasts for Carysil has risen slightly from 16.0% per annum to 16.5% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.